Two new targeted systemic therapies have been recently introduced as possible treatment options for advanced melanoma, according to an article published online in the European Journal of Cancer Care.
Participants in this study included 343 oncologists who completed online surveys between August and November 2012 (in 11 countries) and March and April 2013 (in another country), following the introduction of the two new treatment agents.
The authors analyzed the results of the surveys and found 23 clinical issues of concern across all countries. Of these 23 issues, the most common were identified as being drug toxicity and tolerability. The second most common was limited treatment effectiveness, followed by limited treatment options.
The findings of the study state that clinical professionals still have concern regarding the limitations of treatment options available to patients despite the promise of two new agents for treating advanced melanoma.
Advanced melanoma is a life-threatening cancer with limited life expectancy. The recent introduction of new targeted systemic therapies has provided clinicians with the means to potentially extend survival for the first time. However, the chance of cure remains very low and treatment-induced toxicity is well described.
READ FULL ARTICLE
From Wiley Online Library
Please login or register first to view this content.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.